Cervical myelography with Amipaque: seven years experience

Area of Science:

• Neuroradiology
• Pharmacology
• Medical Imaging

Background:

• Amipaque (Metrizamide) is an intrathecal contrast agent used in myelography.
• Its use can lead to adverse effects and complications, influenced by dose and concentration reaching the brain surface.
• Cervical myelography poses a specific risk of undiluted contrast material entering the cranial cavity.

Purpose of the Study:

• To highlight the potential adverse effects and complications associated with intrathecal Amipaque (Metrizamide) administration.
• To emphasize the importance of understanding the physical, physiological, and pathophysiological properties of the contrast medium.
• To underscore the necessity of careful patient and diagnostic evaluation for safe and effective cervical myelography.

Main Methods:

• Review of the properties of Amipaque (Metrizamide).
• Analysis of risks associated with cervical myelography.
• Emphasis on patient evaluation and procedural technique.

Main Results:

• Adverse effects are dose- and concentration-dependent.
• Cervical myelography carries a risk of contrast material escaping into the cranial cavity.
• Proper management requires knowledge of the medium's properties.

Conclusions:

• Thorough understanding of Amipaque (Metrizamide)'s properties is crucial for managing intrathecal injections.
• Careful patient selection and diagnostic assessment are mandatory.
• Correct cervical myelography technique ensures diagnostic accuracy with minimal complications.